RT Journal Article
SR Electronic
T1 <strong>Prospective </strong><strong>evaluation of <sup>99m</sup>Tc MDP scintigraphy, <sup>18</sup>F NaF/<sup>18</sup>F FDG PET/CT and WBMRI in patients with breast and prostate cancers</strong>
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 1305
OP 1305
VO 56
IS supplement 3
A1 Iagaru, Andrei
A1 Minamimoto, Ryogo
A1 Mosci, Camila
A1 Jamali, Mehran
A1 Barkhodari, Amir
A1 Loening, Andreas
A1 Taviani, Valentina
A1 Mittra, Erik
A1 Gambhir, Sanjiv
A1 Vasanawala, Shreyas
YR 2015
UL http://jnm.snmjournals.org/content/56/supplement_3/1305.abstract
AB 1305 Objectives We prospectively compared the combined NaF/FDG PET/CT and WBMRI against 99mTc-MDP in patients with breast and prostate cancers.Methods 15 men with prostate cancer and 15 women with breast cancer, 34-84 year-old (mean: 61±13), referred for 99mTc-MDP bone scans were prospectively enrolled from Nov 2012 to Jul 2014. NaF and FDG were injected from separate syringes. PET/CT and MRI were done 1-21 days apart (mean: 2.5±3.9). WBMRI protocol consisted of T1-weighted, STIR, DWI, and contrast-enhanced T1-weighted imaging. Lesions detected with each test were tabulated and the results were compared.Results 1 patient with a negative bone scan and PET/CT could not tolerate the WBMRI. 12 patients had no bone metastases identified on any of the 3 scans. Bone scan showed osseous metastases in 14 patients, while the combined NaF/FDG PET/CT and WBMRI showed bone metastases in 4 more and 3 more, respectively (18 patients total). More numerous bone findings were noted on PET/CT than on WBMRI in 7 patients. Lesions outside the skeleton were identified by PET/CT and WBMRI in 10 patients. In 1 patient MRI showed brain metastases not noted on PET/CT. In 1 patient PET/CT showed axillary and internal mammary lymph nodes not described on MRI.Conclusions NaF/FDG PET/CT and WBMRI are superior to 99mTc-MDP scintigraphy for evaluation of skeletal disease. Further, PET/CT and WBMRI detected extra-skeletal disease that may change the management of these patients. A combination of NaF/FDG PET and WBMRI may provide the most accurate staging of patients with breast and prostate cancers. Larger cohorts are needed in order to confirm these preliminary findings, ideally using the newly introduced simultaneous PET/MRI scanners.Research Support GE Healthcare